^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Castration-Resistant Prostate Cancer

    Associations

    News

    Trials
    14h
    Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=217, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1)
    |
    HER-2 negative
    |
    fulvestrant • letrozole
    15h
    KNIGHTS: High-Risk Metachronous Oligometastatic Prostate Cancer Trial (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, University of Maryland, Baltimore | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CD4 (CD4 Molecule) • RAD54L (DNA Repair And Recombination Protein RAD54)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • RAD51B mutation • RAD54L mutation
    |
    Zejula (niraparib) • abiraterone acetate • prednisone
    17h
    InavoPC: A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Hoffmann-La Roche
    Trial initiation date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Itovebi (inavolisib)
    18h
    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=85, Active, not recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Aug 2030 --> May 2027 | Trial primary completion date: Jan 2030 --> May 2027
    Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation • FOLH1 positive
    |
    Lynparza (olaparib) • FPI-2265
    19h
    A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=208, Recruiting, Novartis Pharmaceuticals
    New P1 trial • First-in-human
    |
    Xtandi (enzalutamide) • abiraterone acetate
    1d
    Functional and genomic characterization of LCN2-deficient PC-3 cells reveals insights into prostate cancer progression. (PubMed, Front Mol Biosci)
    Consistent with these observations, spectral karyotyping (SKY) and analysis of spontaneously occurring micronuclei revealed an elevated level of chromosomal aberrations in the LCN2-deficient cell line. These results emphasize the significance of LCN2 in driving prostate cancer aggressiveness and provide a foundation for exploring targeted interventions that disrupt LCN2-mediated pathways in advanced disease.
    Journal
    |
    LCN2 (Lipocalin-2)
    1d
    AxeCan: Axelopran for Advanced Cancer in Patients Receiving Opioids (clinicaltrials.gov)
    P2, N=34, Recruiting, HealthPartners Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PGR (Progesterone receptor)
    1d
    A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (clinicaltrials.gov)
    P3, N=600, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • mevrometostat (PF-06821497)
    1d
    BNT324-03: A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=736, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • prednisone • BNT324
    1d
    A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=228, Recruiting, Regeneron Pharmaceuticals | N=370 --> 228 | Trial completion date: Jan 2027 --> Mar 2030 | Trial primary completion date: Jan 2027 --> Mar 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    nezastomig (REGN5678)
    1d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, University of Michigan Rogel Cancer Center | N=39 --> 20
    Enrollment change
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    1d
    OMAHA-003: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1310, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2028 --> Feb 2030
    Trial completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)